UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net income	$ 16,473	$ 14,788	$ 10,798
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	612	636	655
Amortization	6,417	6,645	6,515
Provision for losses on accounts receivable	30	24	(5)
Amortization of operating lease assets	53	3	39
Loss/(Gain) on disposal of assets	0	0	1
Deferred income taxes	(401)	(92)	(26)
Stock-based compensation expense	183	166	160
Tax benefit attributable to exercise of stock options	6	39	7
Accounts receivable	(511)	(1,088)	617
Other receivables	(14)	(42)	45
Inventories	(2,353)	(485)	924
Prepaid expenses and other current assets	(64)	(81)	108
Accounts payable	464	(23)	(308)
Accrued expenses	252	713	607
Net cash provided by operating activities	21,147	21,203	20,137
Cash flows from investing activities
Property and equipment	(809)	(552)	(860)
Intangible assets	(9)	0	0
Net cash (used in) investing activities	(818)	(552)	(860)
Cash flows from financing activities
Proceeds from issuance of common stock - options	174	560	358
Common stock purchased and retired	(2,495)	0	(6,976)
Dividends paid	(3,163)	(11,465)	(4,116)
Net cash (used in) financing activities	(5,484)	(10,905)	(10,734)
Effect of exchange rate changes on cash	(767)	(362)	260
Net increase in cash and cash equivalents	14,078	9,384	8,803
Cash at beginning of year	60,974	51,590	42,787
Cash at end of year	75,052	60,974	51,590
Cash paid during the period for income taxes	4,970	4,617	3,186
Cash paid during the period for interest	$ 0	$ 0	$ 0